Category Archives: Insulin Delivery

Beta Bionics Raises $50M, but No Lilly Investment

Beta Bionics announced it has secured $50M thus far in a Series B round. Interestingly, the press release states Novo has participated in the Series B, but there was no mention of Lilly. Recall, Both Novo and Lilly previously invested $5M each in the Series A financing. Zealand also committed $5M to the Series B fresh off its $205M cash injection from the sale of Soliqua/Lyxumia royalties. Below, FENIX provides thoughts on the Beta Bionics financing including Lilly’s apparent decision to refrain from further investment.

This content is for Read Less members only.
Already a member? Log in here

Sanofi Restructures GBUs; Stefan Oelrich Moves to Bayer

Less than 3 years after reorganizing the company into 5 Global Business Units (GBUs), Sanofi is once again restructuring the organization. Now, Sanofi is creating Primary Care and China & Emerging Markets GBUs, which will replace the Diabetes and Cardiovascular (DCV) and General Medicines & Emerging Markets (GEM) GBUs. As part of the transition, Stefan Oelrich, head of the DCV business, is leaving Sanofi to join Bayer’s Board of Management and lead its Pharmaceuticals Division. The transition is set to take effect by the beginning of 2019. Below, FENIX provides thoughts Sanofi’s reorganization with insight on the potential impact on its diabetes business.

This content is for Read Less members only.
Already a member? Log in here

Insulet CEO Succession

Insulet announced that as of January 1, 2019, Shacey Petrovic (pictured below) will succeed Patrick Sullivan as Insulet’s CEO. For the last two years, Petrovic has served as the company’s President and Chief Operating Officer. Below, FENIX provides thoughts on the CEO succession and impact to Insulet moving forward.

This content is for Read Less members only.
Already a member? Log in here

Livongo-Abbott Integration with Libre Pro

Livongo announced a partnership with Abbott to integrate the FreeStyle Libre Pro into the Livongo for Diabetes program. The integration with a professional (retrospective) CGM makes sense given Livongo’s focus on patient education and behavior-based treatment. Below, FENIX provides a unique perspective that the Abbott partnership could signal a limitation in Livongo’s diabetes solution.

This content is for Read Less members only.
Already a member? Log in here

Sanofi DCV CMO Leaves

Riccardo Perfetti (pictured below), Sanofi’s VP Medical Affairs and Head of the DCV Global Medical Team, has reportedly left Sanofi to serve as the CMO of Applied Therapeutics. Perfetti had been with Sanofi since October 2007.

This content is for Read Less members only.
Already a member? Log in here

Medtronic Guardian Sensor 3 CGM Now Integrated with 630G

Medtronic has started notifying HCPs that its 630G sensor augmented pump (SAP) with low glucose suspend is now available with the Guardian Sensor 3 CGM. This is the same sensor that is being used with the 670G hybrid closed-loop as well as the standalone Guardian Connect CGM system. Medtronic did not issue a press release on the new 630G/Guardian Sensor 3 integration. Below, FENIX provides observations and thoughts on the upgraded sensor integration.

This content is for Read Less members only.
Already a member? Log in here

$TNDM Breaks $40 Barrier

Tandem’s stock price has broken the $40 mark (see chart below) for the first time since Medtronic became United Healthcare’s preferred in-network insulin pump provider in May 2016. Below, FENIX provides its thoughts on Tandem’s future market opportunity.

This content is for Read Less members only.
Already a member? Log in here

Diabetes Tech Update: Xeris, Tandem, and Voluntis

Xeris, Tandem, and Voluntis have announced news related to their respective diabetes business units. Below, FENIX has provided a summary of these updates, the most interesting of which is from Xeris.

This content is for Read Less members only.
Already a member? Log in here

Medtronic Launches 670G & Guardian Connect Gamification App

Medtronic announced the launch of its “Inner Circle” patient engagement program for patients on either the 670G hybrid closed-loop or the standalone Guardian Connect CGM. Recall, Medtronic initially disclosed its plans for Inner Circle during the June 2018 Investor Day.

This content is for Read Less members only.
Already a member? Log in here